177Lu-LNC1011

DRUG2 trials

Sponsors

Peking Union Medical College Hospital, Affiliated Hospital of Jiangnan University

Conditions

Metastatic Castration-resistant Prostate CancerPSMA PET-Positive Castration-Resistant Prostate Cancer

Phase 1

177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer

RecruitingNCT06250244

Peking Union Medical College HospitalMetastatic Castration-resistant Prostate Cancer

Start: 2023-05-01End: 2025-10-01Target: 12Updated: 2024-12-11

Unknown Phase

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

CompletedNCT06809426

Affiliated Hospital of Jiangnan UniversityPSMA PET-Positive Castration-Resistant Prostate Cancer

Start: 2023-08-21End: 2024-10-24Updated: 2025-02-05

Related Papers

PSMA-targeted radioligand therapy with [<sup>177</sup>Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study.

2025-04-10